As a global leader in the treatment of, research on, and education in gastric cancer, the Gastric Cancer Center endeavors to provide the best treatment service to all patients.
To provide the best examination and treatment to individual patients, the Gastric Cancer Center holds multidisciplinary conference on cases taken part in by the Division of Gastrointestinal Surgery, Division of Gastroenterology, Division of Hematology/Medical Oncology, Department of Radiology, Department of Pathology, and Department of Nuclear Medicine, Also it performs individually tailored treatment in terms of surgical methods. Since the multidisciplinary conference started in 2005, it has accumulated 406 conferences by 2021.
As a single center, it reached 20,000 gastric cancer surgeries in 2007, which was unprecedented worldwide, and it reached 30,000 cases in 2019. It provides world-class standardized treatment service based on its accumulated experience of approximately 1000 gastric cancer surgeries per year.
In particular, the center has led research on the domestic dissemination of laparoscopic pylorus-preserving gastrectomy, which is a function preservation surgery with little weight loss and few complications after surgery, and is gradually expanding the application of state-of-the-art surgeries such as laparoscopic and robotic surgeries.
As for certain types of early gastric cancer and gastric adenoma, endoscopic excision has been performed actively as well, with endoscopic submucosal dissection (ESD) performed 573 times in 2020. In addition, the Gastrointestinal Endoscopy Center at the Cancer Hospital provides gastroscopy service on the day of the visit to the hospital to enhance patients’ convenience and satisfaction and performs gastroscopy 53 times on an average per day.
Due to various interventional procedures in the radiology department, patients with complications after gastric cancer surgery were recovered without the additional surgery. 710 cases of interventions were performed in 2020.
Specialized nurses help patients take same-day exams including CT scanning by providing relevant information in advance, and, during ambulatory care after surgery, patients’ recovery is assisted through counseling with professional nutritionists.
The center has been acknowledged across the globe also in gastric cancer research so that its systematically managed clinical data were used as major supporting evidence in the field of gastric cancer in the 8th edition (2018) of the UICC/AJCC TNM Classification of Malignant Tumors, which is the worldwide standard of cancer staging.
The center plays a leading role in multinational research. It has led research on the stability of laparoscopic gastrectomy for gastric cancer (series of KLASS trials) It has published the finding that adjuvant chemotherapy after surgery for stages II and III gastric cancer can decrease the recurrence rate (CLASSIC), thus presenting a standard for the treatment of gastric cancer (Lancet, 2012). The center has contributed to a study that aims at demonstrating the role of gastrectomy in stage IV gastric cancer (REGATTA), which was conducted jointly by Korea, Japan, and Singapore. The center’s research on HER2-targeted therapy (TOGA) likewise has been evaluated as having opened new horizons in gastric cancer targeted therapy (Lancet, 2010).
Figures from around the world have visited the center to observe its outstanding treatment of and research on gastric cancer.
More than 300 overseas medical personnel (surgeons, physicians, nurses, scientists and students) have visited Gastric Cancer Center from Germany, the United States, Japan, China, Singapore, Italy, India, etc. to learn knowledge and skills since 2007.